This finding suggests the usefulness of a GLP-1R agonist in PNDM characterized by impaired insulin secretion as the main pathophysiology, which is different from that of type 2 diabetes consisting of insulin resistance and impaired insulin secretion. Here, GLP1R is linked to Insulin resistance.